Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PRKACA | P17612 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.49 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.49 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.49 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.49 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.49 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31647127 | 0.98 | HRH1 (0.53) | HRH1IKBKBROCK1ROCK2PRKACA | |
| Hydrochloric Acid SCHEMBL2777776 | 0.98 | HRH1 (0.53) | HRH1IKBKBROCK1ROCK2PRKACA | |
| SCHEMBL22278225 | 0.90 | PRKCZ (0.55) | ROCK1SLC6A2HTR1APRKCZHTR2C | |
| SCHEMBL22278068 | 0.90 | PRKCZ (0.55) | ROCK1SLC6A2HTR1APRKCZHTR2C | |
| SCHEMBL6213195 | 0.90 | PRKCZ (0.55) | ROCK1SLC6A2HTR1APRKCZHTR2C | |
| Hydrochloric Acid SCHEMBL22266096 | 0.88 | PRKCZ (0.54) | ROCK1SLC6A2HTR1APRKCZHTR2C | |
| Hydrochloric Acid SCHEMBL22265775 | 0.88 | PRKCZ (0.54) | ROCK1SLC6A2HTR1APRKCZHTR2C | |
| SCHEMBL3126596 | 0.87 | HTR2C (0.48) | HRH1IKBKBROCK1ROCK2PRKACA | |
| SCHEMBL24716435 | 0.87 | PTGS1 (0.46) | HRH1SLC6A2SLC6A3HRH3SLC6A4 | |
| SCHEMBL4718730 | 0.85 | HRH3 (0.54) | HRH1IKBKBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689650-B | Benzamide derivatives P2X7 receptor antagonists containing phenoxypiperidine or benzyloxypiperidine and thiazole | 阿克萨姆股份公司 | 2022-11-25 | — | — | CN | disclosed |
| EP-3507287-B1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2020-07-15 | — | — | EP | disclosed |
| EP-3507287-B1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2020-07-15 | — | — | EP | disclosed |
| US-10669267-B2 | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2020-06-02 | — | — | US | disclosed |
| US-10669267-B2 | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2020-06-02 | — | — | US | disclosed |
| EP-3507287-A1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | AXXAM S.p.A. (IT) | 2019-07-10 | — | — | EP | disclosed |
| US-20190194180-A1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-20190194180-A1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| WO-2018041563-A1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2018-03-08 | — | — | WO | disclosed |
| EP-3290416-A1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES AND THEIR USE AS P2X7 RECEPTOR ANTAGONIST | AXXAM S.p.A. (IT) | 2018-03-07 | — | — | EP | disclosed |
| EP-1263725-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| WO-2001092227-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001062757-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062728-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062729-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194180-A1 | SUBSTITUTED N-[2-(4-PHENOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE AND N-[2-(4-BENZYLOXYPIPERIDIN-1-YL)-2-(1,3-THIAZOL-5-YL)ETHYL]BENZAMIDE DERIVATIVES P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX2, P2RX1 | HRH1 523/4885IKBKB 795/4885ROCK1 3968/4885 |
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | HRH1 39/4885IKBKB 767/4885ROCK1 1601/4885 |
| US-10669267-B2 | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | P2RX7, P2RX2, P2RX1 | HRH1 523/4885IKBKB 795/4885ROCK1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.